SOMAÍ Pharmaceuticals is a leading EU-GMP vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio.
Michael Sassano brought his expertise in product development from the US market with him. As the medical cannabis explosion continues in Europe and around the globe, Spain has finally approved medical cannabis access for its population. See below Michael Sassano’s article about recent Spain’s medical cannabis development.
Article starts here:
As I pointed out in my last article, Spain has been a strange experiment in cannabis access. The country allowed social clubs to purchase unregulated market products to sell to its members, but medical patients had no access to quality pharmaceuticals. As Spain turns the corner to more improvements in its cannabis market, medical patients can hail this first step as a big win.
A good start for Spanish therapeutic cannabis
After three years of political delays, Spain has taken a big step toward starting what it promised in terms of equitable access to quality medical cannabis. There is much to be happy about in the regulations — and many further improvements to hope for.
Indications included in Spanish medical cannabis access
